Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Approves Shire’s Once-Daily INTUNIV for the Treatment of ADHD in Children andAdolescents Aged 6 to 17

By Pharmaceutical Processing | September 3, 2009

Shire plc has received approval from the FDA for INTUNIV(TM) (guanfacine) Extended Release Tabletsfor the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) inchildren and adolescents aged 6 to 17 years. INTUNIV, a once-dailyformulation of guanfacine, is the first selective alpha-2A adrenergicreceptor agonist approved for the treatment of ADHD. Although the mechanismof action is unknown, INTUNIV is thought to directly engage receptors foundin the prefrontal cortex – an area of the brain that has been linked inpreclinical research to ADHD. Stimulation of the postsynaptic alpha-2Areceptors is thought to strengthen working memory, reduce susceptibility todistraction, improve attention regulation, improve behavioral inhibition, andenhance impulse control. “Shire is proud to introduce INTUNIV, providing clinicians, patients, andtheir families with a novel ADHD treatment option,” said Mike Cola, Presidentof Shire Specialty Pharmaceuticals. “This is a complex disorder in whichpatients may present with multiple symptoms and behaviors that can bedisruptive. INTUNIV expands the Shire ADHD portfolio with a nonscheduledmedication, allowing clinicians to optimize their overall approach towardmanaging ADHD and may help provide symptom control for children and teenswith ADHD who often have difficulty responding appropriately to everydaysituations and challenges.” Once-daily INTUNIV is expected to be available in US pharmacies inNovember and will come in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg).INTUNIV will be marketed in the United States by the existing Shire ADHDsales team of nearly 600 representatives. INTUNIV is not a controlledsubstance and has no known potential for abuse or dependence.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE